Thomas B. Okarma, Ph.D., M.D.,
has served as our President, Chief Executive Officer and a member of our board of directors
since July 1999. He is also a director of Geron Bio-Med Limited, a United Kingdom company and
Geron's wholly-owned subsidiary, and TA Therapeutics, Ltd., a Hong Kong company and Geron's
majority-owned subsidiary. From May 1998 until July 1999, Dr. Okarma was the Vice President
of Research and Development. From December 1997 until May 1998, Dr. Okarma was Vice
President of Cell Therapies. Dr. Okarma currently serves on the Board of BIO and was Chairman
of the Board of Overseers of Dartmouth Medical School from 2000 to 2007. In 1985, Dr. Okarma
founded Applied Immune Sciences, Inc. and served initially as Vice President of Research and
Development and then as chairman, chief executive officer and a director of Applied Immune
Sciences, until 1995 when it was acquired by Rhone-Poulenc Rorer. Dr. Okarma was a Senior
Vice President at Rhone-Poulenc Rorer from the time of the acquisition of Applied Immune
Sciences until December 1996. From 1980 to 1992, Dr. Okarma was a member of the faculty of
the Department of Medicine at Stanford University School of Medicine. Dr. Okarma holds a A.B.
from Dartmouth College, a M.D. and Ph.D. from Stanford University and an executive M.B.A. from
Stanford Graduate School of Business.
David L. Greenwood
has served as our Chief Financial Officer, Treasurer and Secretary since August 1995 and our
Executive Vice President since January 2004. He is also a director of our wholly-owned
subsidiary, Geron Bio-Med Limited, our majority-owned subsidiary, TA Therapeutics, Ltd.,
ViaGen, Inc., an Arizona corporation, and Clone International, an Australian company. From
August 1999 until January 2004, Mr. Greenwood also served as our Senior Vice President of
Corporate Development. From April 1997 until August 1999, Mr. Greenwood served as our Vice
President of Corporate Development. He also serves on the Board of Regents for Pacific Lutheran
University. From 1979 until joining us, Mr. Greenwood held various positions with J.P. Morgan &
Co. Incorporated, an international banking firm. Mr. Greenwood holds a B.A. from Pacific
Lutheran University and a M.B.A. from Harvard Business School.
Stephen M. Kelsey, M.D., F.R.C.P., F.R.C.Path., has
served as our as Executive Vice President and Chief Medical Officer, Oncology since April 2009.
From June 2002 until April 2009, Dr. Kelsey held various positions at Genentech, Inc., most
recently as vice-president, clinical hematology/oncology. From June 2000 to June 2002, Dr.
Kelsey was the director of clinical affairs at Pharmacia Corporation (SUGEN, Inc.) in South San
Francisco and director of global clinical development (oncology) at Pharmacia Corporation in
Milan, Italy. From July 1993 to June 2000, Dr. Kelsey served as a senior lecturer in
hematology/oncology at St. Bartholomews and the Royal London School of Medicine and
Dentistry and visiting fellow at Vancouver General Hospital and Terry Fox Laboratories. Dr. Kelsey
earned his B.Sc. in Pharmacology, M.B., Ch.B., and Doctorate of Medicine (M.D.) degrees from the
University of Birmingham in the United Kingdom.
David J. Earp, J.D. Ph.D.,
has served as our Senior Vice President of Business Development and Chief Patent Counsel since
May 2004. He is also a director of our majority-owned subsidiary, TA Therapeutics, Ltd. and
ViaGen, Inc., an Arizona corporation. From October 1999 until May 2004, Dr. Earp served as our
Vice President of Intellectual Property. From 1992 until joining us in June 1999, Dr. Earp was
with the intellectual property law firm of Klarquist Sparkman Campbell Leigh and Whinston, LLP.
Dr. Earp holds a B.Sc. in microbiology from the University of Leeds, England, a Ph.D. from the
biochemistry department of The University of Cambridge, England, and conducted postdoctoral
research at the University of California at Berkeley/U.S.D.A. Plant Gene Expression Center. He
received his J.D. from the Northwestern School of Law of Lewis and Clark College in Portland,
Oregon.
Melissa A. Kelly Behrs
has served as our Senior Vice President, Therapeutic Development, Oncology since January 2007.
Ms. Behrs served as our Vice President of Oncology from January 2003 until January 2007. From
April 2002 until January 2003, Ms. Behrs served as our Vice President of Corporate Development.
From April 2001 until April 2002, Ms. Behrs served as our General Manager of Research and
Development Technologies. Ms. Behrs joined us in November 1998 as Director of Corporate
Development. From 1990 to 1998, Ms. Behrs worked at Genetics Institute, Inc., serving initially as
Assistant Treasurer and then as Associate Director of Preclinical Operations where she was
responsible for all business development, regulatory, and project management activities for the
Preclinical Development function. Ms. Behrs received a B.S. from Boston College and an M.B.A.
from Babson College.
Jane S. Lebkowski, Ph.D.,
has served as our Senior Vice President, Chief Scientific Officer, Regenerative Medicine since
2009 and Senior Vice President of Regenerative Medicine since January 2004. From August 1999
until January 2004, Dr. Lebkowski served as our Vice President of Regenerative Medicine. From
April 1998 until August 1999, Dr. Lebkowski served as our Senior Director, Cell and Gene
Therapies. From 1986 until joining us in 1998, Dr. Lebkowski served as Vice President, Research
and Development at Applied Immune Sciences. In 1995, Applied Immune Sciences was acquired
by Rhone-Poulenc Rorer, at which time Dr. Lebkowski was appointed Vice President, Discovery &
Product Development. Dr. Lebkowski received a B.S. in chemistry and biology from Syracuse
University and received her Ph.D. from Princeton University.
Katharine E. Spink, Ph.D.,
has served as our Vice President of Operations, Regenerative Medicine Programs since February
2009. From January 2008 until February 2009, Dr. Spink served as our Senior Director of
Regenerative Medicine Program Operations. From January 2007 until January 2008, Dr. Spink
served as our Program Director for Cardiovascular Disease. Dr. Spink joined Geron in December
2003, and served various roles within our Corporate Development group until January 2007.
Prior to Geron, Dr. Spink was with the global management consulting firm McKinsey & Company,
where she advised clients in the biotechnology, pharmaceutical, and medical device industries on
matters relating to R&D strategy, business development, and marketing. Dr. Spink holds a B.A. in
biochemistry from Rice University, and a Ph.D. in cancer biology from Stanford University.
